Journal of Antimicrobial Chemotherapy (1994) 33, 215-222
© 1994 The British Society for Antimicrobial Chemotherapy
research-article |
Susceptibility of Moraxella catarrhalis isolates to ß-lactam antibiotics in relation to ß-lactamase pattern
a Department of Medical Microbiology, The London Hospital Medical College Turner Street, London El 2AD, UK b Section of Infectious Diseases, Department of Medicine, Veterans General Hospital-Taipei 201, Section 2, Shih-Pai Road, Taipei 11217, Taiwan, Republic of China
Received 2 December 1992; accepted 20 September 1993
Moraxella catarrhalis isolates (n = 413) were collected from 20 clinical laboratories in England and Scotland in 1991 and were examined for ß-lactamase production by isoelectric focusing. ß-lactamases were found in 375 isolates of which, 349 (93.1%) had BRO-1 enzyme and 26 (6.9%) had BRO-2. Minor variation in electrofocusing pattern occurred within both enzyme types. Ampicillin MICs for BRO-1 producers were 25-fold higher than for non-producers, but those for BRO-2 producers were raised only four-fold. MICs of cefaclor, cefixime, loracarbef, co-amoxiclav and cefetamet generally were two- to four-fold higher for BRO-1 producers than for BRO-2 producers and enzyme non-producers. Similarly, the inhibition zones of discs containing cefaclor, cefixime, loracarbef or co-amoxiclav were smaller for BRO-1 producers than for non-producers. Amongst the compounds tested, cefetamet seemed the least affected by ß-lactamase production in both MIC and disc tests. Overall, these results indicate that BRO-1 enzyme predominates amongst M. catarrhalis isolates from the UK, as in other countries, and suggest that BRO-1 production gives slight protection against many of the newer oral ß-lactams as well as causing ampicillin resistance.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. M. Bell, J. D. Turnidge, and R. N. Jones Development of a Disk Diffusion Method for Testing Moraxella catarrhalis Susceptibility Using Clinical and Laboratory Standards Institute Methods: a SENTRY Antimicrobial Surveillance Program Report J. Clin. Microbiol., July 1, 2009; 47(7): 2187 - 2193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Deshpande, H. S. Sader, T. R. Fritsche, and R. N. Jones Contemporary Prevalence of BRO {beta}-Lactamases in Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (North America, 1997 to 2004). J. Clin. Microbiol., October 1, 2006; 44(10): 3775 - 3777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Lafontaine, D. Wall, S. L. Vanlerberg, H. Donabedian, and D. D. Sledjeski Moraxella catarrhalis Coaggregates with Streptococcus pyogenes and Modulates Interactions of S. pyogenes with Human Epithelial Cells Infect. Immun., November 1, 2004; 72(11): 6689 - 6693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Levy and E. S. Walker BRO {beta}-lactamase alleles, antibiotic resistance and a test of the BRO-1 selective replacement hypothesis in Moraxella catarrhalis J. Antimicrob. Chemother., February 1, 2004; 53(2): 371 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Schmitz, A. Beeck, M. Perdikouli, M. Boos, S. Mayer, S. Scheuring, K. Kohrer, J. Verhoef, and A. C. Fluit Production of BRO {beta}-Lactamases and Resistance to Complement in European Moraxella catarrhalis Isolates J. Clin. Microbiol., April 1, 2002; 40(4): 1546 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-G. Hu, J. Chen, J. F. Battey, and X.-X. Gu Enhancement of Clearance of Bacteria from Murine Lungs by Immunization with Detoxified Lipooligosaccharide from Moraxella catarrhalis Conjugated to Proteins Infect. Immun., September 1, 2000; 68(9): 4980 - 4985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Richter, P. L. Winokur, A. B. Brueggemann, H. K. Huynh, P. R. Rhomberg, E. M. Wingert, and G. V. Doern Molecular Characterization of the beta -Lactamases from Clinical Isolates of Moraxella (Branhamella) catarrhalis Obtained from 24 U.S. Medical Centers during 1994-1995 and 1997-1998 Antimicrob. Agents Chemother., February 1, 2000; 44(2): 444 - 446. [Abstract] [Full Text]
|
|
|
|
|
|
E. S. Walker, C. L. Neal, E. Laffan, J. H. Kalbfleisch, S. L. Berk, and F. Levy Long-term trends in susceptibility of Moraxella catarrhalis: a population analysis J. Antimicrob. Chemother., February 1, 2000; 45(2): 175 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Bootsma, P. C. Aerts, G. Posthuma, T. Harmsen, J. Verhoef, H. van Dijk, and F. R. Mooi Moraxella (Branhamella) catarrhalis BRO beta -Lactamase: a Lipoprotein of Gram-Positive Origin? J. Bacteriol., August 15, 1999; 181(16): 5090 - 5093. [Abstract] [Full Text]
|
|
|
|
|
|
R. K. Budhani and J. K. Struthers Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: Investigation of the Indirect Pathogenic Role of beta -Lactamase-Producing Moraxellae by Use of a Continuous-Culture Biofilm System Antimicrob. Agents Chemother., October 1, 1998; 42(10): 2521 - 2526. [Abstract] [Full Text]
|
|